Drug intelligence / Profile preview

paraxanthine

Development stage
Unknown
Lead developer
NNB Nutrition
Modality
Small Molecules
Administration
Oral
01

Overview

**Paraxanthine** is a naturally occurring compound and the primary metabolite of caffeine in humans. Enfinity, the branded form of paraxanthine, is marketed as a safer and more consistent alternative to caffeine for use as an energy and focus ingredient in dietary supplements. Rather than being metabolized from caffeine, it is delivered directly, bypassing the intermediate compounds (theophylline and theobromine) and purportedly reducing caffeine-associated side effects like jitters, anxiety, and crashes. Enfinity is used in energy, cognition, and performance supplements, supported by clinical and preclinical research[2][10]. Its proposed mechanism is central nervous system stimulation, similar to caffeine, but with a claimed smoother effect and reduced bitterness, making it attractive for product formulation. It is promoted for boosting energy, wakefulness, reaction speed, focus, mood, and thermogenesis[2].

Brand names
Enfinity
Other names
1,7-dimethylxanthine
02

Targets

ADORA2A (Adenosine A₂A Receptor)ADORA3 (Adenosine A3 receptor)ADORA2B (Adenosine A2B receptor)ADORA1 (Adenosine receptor A1 subtype)PDE9A (Phosphodiesterase 9A)

Beyond the preview

Go deeper on paraxanthine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on paraxanthine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call